<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Health Sci J</journal-id><journal-id journal-id-type="iso-abbrev">Curr Health Sci J</journal-id><journal-id journal-id-type="publisher-id">CHSJ</journal-id><journal-title-group><journal-title>Current Health Sciences Journal</journal-title></journal-title-group><issn pub-type="ppub">2067-0656</issn><issn pub-type="epub">2069-4032</issn><publisher><publisher-name>Medical University Publishing House Craiova</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6243512</article-id><article-id pub-id-type="publisher-id">2015.41.04.03</article-id><article-id pub-id-type="doi">10.12865/CHSJ.41.04.03</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>NOD2 Arg702Trp Polymorphism in Romanian Patients with Gastric Cancer </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>FLORESCU</surname><given-names>D.N.</given-names></name><xref ref-type="aff" rid="AFF1">1</xref></contrib><contrib contrib-type="author"><name><surname>TUDORAŞCU</surname><given-names>D.R.</given-names></name><xref ref-type="aff" rid="AFF2">2</xref></contrib><contrib contrib-type="author"><name><surname>BURADA</surname><given-names>F.</given-names></name><xref ref-type="aff" rid="AFF3">3</xref><xref ref-type="aff" rid="AFF4">4</xref></contrib><contrib contrib-type="author"><name><surname>CUCU</surname><given-names>M.G.</given-names></name><xref ref-type="aff" rid="AFF4">4</xref></contrib><contrib contrib-type="author"><name><surname>CIUREA</surname><given-names>M.E.</given-names></name><xref ref-type="aff" rid="AFF5">5</xref></contrib></contrib-group><aff id="AFF1"><label>1</label> Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, Romania</aff><aff id="AFF2"><label>2</label> Internal Medicine II, University of Medicine and Pharmacy of Craiova, Romania</aff><aff id="AFF3"><label>3</label> Department of Medical Genetics, University of Medicine and Pharmacy Craiova, Romania </aff><aff id="AFF4"><label>4</label> Human Genomics Laboratory, University of Medicine and Pharmacy of Craiova, Romania</aff><aff id="AFF5"><label>5</label> Plastic and Reconstructive Surgery, University of Medicine and Pharmacy of Craiova, Romania</aff><author-notes><corresp id="cor1">Corresponding Author: Dan Nicolae Florescu,
<named-content content-type="dept">Research Center of Gastroenterology and Hepatology</named-content><institution>University of Medicine and Pharmacy of Craiova, </institution><country>Romania</country><email>dannicolaeflorescu@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2015</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2015</year></pub-date><volume>41</volume><issue>4</issue><fpage>307</fpage><lpage>310</lpage><history><date date-type="received"><day>21</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>01</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>Copyright © 2015, Medical University Publishing House Craiova</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Purpose. </plain></SENT>
<SENT sid="2" pm="."><plain>Our study aimed to assess a possible correlation between NOD2 Arg702Trp (rs2066844) polymorphism and gastric cancer risk in a Romanian population. </plain></SENT>
<SENT sid="3" pm="."><plain>Material/Methods. </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 322 subjects (72 patients with gastric adenocarcinoma and 250 healthy controls) were included. </plain></SENT>
<SENT sid="5" pm="."><plain>Genomic DNA was extracted from blood leukocytes and NOD2 Arg702Trp polymorphism was genotyped by Real-Time PCR using specific TaqMan probes. </plain></SENT>
<SENT sid="6" pm="."><plain>Results. </plain></SENT>
<SENT sid="7" pm="."><plain>No statistically significant difference was observed between gastric cancer patients and controls when we compared one genotype with other genotype (the CC genotype serves as reference) (OR 0.45, 95% CI: 0.10 - 2.05) or when we compared allele frequencies (the C allele serves as reference) (OR 0.46, 95% CI: 0.11 - 2.04). </plain></SENT>
<SENT sid="8" pm="."><plain>We examined separately the association of this polymorphism with tumor site and histologic type and no correlation was found. </plain></SENT>
<SENT sid="9" pm="."><plain>Conclusion. </plain></SENT>
<SENT sid="10" pm="."><plain>NOD2 Arg702Trp polymorphism is not associated with gastric cancer risk and further investigations are needed to elucidate the contribution of NOD2 gene in gastric carcinogenesis. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author"><kwd>gastric cancer</kwd><kwd>gene</kwd><kwd>NOD2 polymorphism</kwd><kwd>genotype</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="11" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="12" pm="."><plain>Gastric cancer remains a major health problem worldwide and despite the advances in surgery and chemotherapy it is still the second leading cause of cancer death across the world [1]. </plain></SENT>
<SENT sid="13" pm="."><plain>Currently, it is accepted a multifactorial model in gastric carcinogenesis where environmental factors, diet and genetic susceptibility interact in producing the host disease. </plain></SENT>
</text></p><p><text><SENT sid="14" pm="."><plain>NOD2 gene, also called CARD15, has been mapped on 16q21 and encodes nucleotide-binding oligomerization domain-containing protein 2. </plain></SENT>
<SENT sid="15" pm="."><plain>NOD2 protein is involved in immune system response produced by macrophages or monocytes and defence processes against invading pathogens. </plain></SENT>
<SENT sid="16" pm="."><plain>Upon triggered by various substances released by viruses or bacteria, NOD2 activates a protein known as nuclear factor-kappa-B (NF-kB), which regulates inflammatory reactions and immune responses [2]. </plain></SENT>
<SENT sid="17" pm="."><plain>Also, NOD2 protein has been proven to have a key role in autophagy, a conserved process that removes cellular parts that are no longer functional or needed. </plain></SENT>
<SENT sid="18" pm="."><plain>NOD2 gene has been linked to several diseases such as Blau syndrome or Crohn disease [3,4,5]. </plain></SENT>
<SENT sid="19" pm="."><plain>The role of NOD2 gene in cancer pathogenesis is controversial, some studies found a positive correlation whereas others were not able to reproduce it [6]. </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>Our study aimed to assess a possible correlation between NOD2 Arg702Trp (rs2066844) polymorphism and gastric cancer risk in a Romanian population. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods"><title><text><SENT sid="21" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec><title><text><SENT sid="22" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="23" pm="."><plain>In this research, we included 72 patients diagnosed with gastric adenocarcinoma and 250 controls. </plain></SENT>
<SENT sid="24" pm="."><plain>All gastric cancer cases were diagnosed by endoscopy and histopathologically confirmed at Clinical Hospital from Craiova, Romania and at the Research Centre in Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, Romania. </plain></SENT>
<SENT sid="25" pm="."><plain>According to Lauren classification gastric cancer cases were classified into two subgroups: intestinal and diffuse type. </plain></SENT>
<SENT sid="26" pm="."><plain>The control group consisted of 250 unrelated and healthy volunteers without gastroduodenal lesions or cancer. </plain></SENT>
<SENT sid="27" pm="."><plain>Written informed consent was obtained from all participants and the Ethics Committee of the University of Medicine and Pharmacy of Craiova approved our study. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="28" pm="."><plain>Taq Man Genotyping assay </plain></SENT>
</text></title><p><text><SENT sid="29" pm="."><plain>Blood samples were collected in EDTA tubes from both groups. </plain></SENT>
<SENT sid="30" pm="."><plain>Genomic DNA was extracted from blood leukocytes using Wizard Genomic DNA Purification Kit (Promega, Madison, WI), following the manufacturer protocol. </plain></SENT>
<SENT sid="31" pm="."><plain>NOD2 Arg702Trp polymorphism was genotyped by Real-Time PCR using specific TaqMan probes for each allele (rs2066844, assay C__11717468_20, Applied Biosystems Foster City, CA). </plain></SENT>
<SENT sid="32" pm="."><plain>RealTime PCR was performed on a ViiA™ 7 Real Time PCR System (Life Technologies, Carlsbad, USA) and components of reaction were: sample DN, Universal Master Mix (Applied Biosystems, Foster City, CA), TaqMan SNP Genotyping Assay 40x (Applied Biosystems, Foster City, CA) and DNase-free, sterile-filtered water. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="33" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="34" pm="."><plain>Genotyping frequencies in control group were tested for compliance with Hardy-Weinberg equilibrium (HWE) using the χ22 test. </plain></SENT>
<SENT sid="35" pm="."><plain>Odds ratios (OR) with 95 % confidence intervals (CIs) were used to determine the association between NOD2 genotypes and gastric cancer A P-value less than 0.05 was considered statistically significant. </plain></SENT>
<SENT sid="36" pm="."><plain>All data were analyzed by SPSS software version 17. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>Results </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>We genotyped 322 subjects (72 patients with gastric adenocarcinoma and 250 healthy controls). </plain></SENT>
<SENT sid="39" pm="."><plain>The mean age of the gastric cancer patients was 67 years . </plain></SENT>
<SENT sid="40" pm="."><plain>The distribution of cases and controls according to age, sex, and ethnicity are comparable. </plain></SENT>
<SENT sid="41" pm="."><plain>All gastric adenocarcinoma were Helicobacter pylori positive. </plain></SENT>
<SENT sid="42" pm="."><plain>The tumor site was cardia in 24 cases and non-cardia in 48 cases (Table 1). </plain></SENT>
<SENT sid="43" pm="."><plain>Histologically, 43 (59.72%) were intestinal-type and 29 (40.28%) were diffuse-type. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results"><title><text><SENT sid="44" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="45" pm="."><plain>We genotyped 322 subjects (72 patients with gastric adenocarcinoma and 250 healthy controls). </plain></SENT>
<SENT sid="46" pm="."><plain>The mean age of the gastric cancer patients was 67 years . </plain></SENT>
<SENT sid="47" pm="."><plain>The distribution of cases and controls according to age, sex, and ethnicity are comparable. </plain></SENT>
<SENT sid="48" pm="."><plain>All gastric adenocarcinoma were Helicobacter pylori positive. </plain></SENT>
<SENT sid="49" pm="."><plain>The tumor site was cardia in 24 cases and non-cardia in 48 cases (Table 1). </plain></SENT>
<SENT sid="50" pm="."><plain>Histologically, 43 (59.72%) were intestinal-type and 29 (40.28%) were diffuse-type. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="51" pm="."><plain>Subjects characteristics </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" border="1"><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>Gastric adenocarcinoma(n=72) </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>Male/Female </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>42/30 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>Age (years), mean±SD </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>67,3±9,1 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>Location - cardia - noncardia </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>24 48 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>Histological type -  intestinal -  diffuse </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>43 29 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="61" pm="."><plain>Risk of gastric cancer by genotype </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" border="1"><tbody><tr><td rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>Polymorphism </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>Gastric cancer (n=72)  </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>Control (n=250) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>OR (95%CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>p value </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>NOD2 rs2066844C/ T Arg702Trp CC CT TT C:T </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>70  (97.22%) 2  (2.78%) 0  (0%) 98.61%  : 1.39%  </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>235  (94.00%) 15    (6.00%) 0    (0%) 97.00% : 3.00% </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>Reference 0.45 (0.10 - 2.05) / 0.46 (0.11 -2.04) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>- 0.25 / 0.26 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p><text><SENT sid="72" pm="."><plain>Risk of gastric cancer according to tumor site and histological type </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" border="1"><tbody><tr><td rowspan="2" colspan="1"/><td colspan="3" rowspan="1"><text><SENT sid="73" pm="."><plain>NOD2 rs2066844C/T Arg702Trp  </plain></SENT>
</text></td><td rowspan="2" colspan="1"><text><SENT sid="74" pm="."><plain>OR   (95%CI);   p </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>CC </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>CT </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>TT </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>Tumor site - Cardia (24) - Noncardia (48) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>23 (95.83%) 47 (97.92%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>1 (4.17%) 1 (2.08%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>0 (0%) 0 (0%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>0.68 (0.09-5.39); 0.70 0.33 (0.04-2.59); 0.22 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>Histological type - Intestinal (43) - Diffuse  (29) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>42 (97.67%) 28 (96.55%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>1 (2.33%) 1 (3.45%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>0 (0%) 0 (0%) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>0.37 (0.05-2.90); 0.28 0.56 (0.071-4.39); 0.55 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="88" pm="."><plain>NOD2 rs2066844 (C/T) in the control group showed no deviation from expected genotype frequencies under the Hardy-Weinberg equilibrium (p&gt;0.05, X2 = 0.24). </plain></SENT>
<SENT sid="89" pm="."><plain>The CC and CT genotype frequencies for both groups are shown in Table 2 and no homozygous for TT genotype was found (Table 2). </plain></SENT>
<SENT sid="90" pm="."><plain>No statistically significant difference was found between gastric cancer patients and healthy subjects when we compared one genotype with other genotype (the CC genotype serves as reference) (OR 0.45, 95% CI: 0.10 - 2.05) or when we compared allele frequencies (the C allele serves as reference) (OR 0.46, 95% CI: 0.11 - 2.04). </plain></SENT>
<SENT sid="91" pm="."><plain>Association of this polymorphism with tumor site and histological type were also examined separately and no important difference was noticed between gastric cancer site (noncardia and cardia) or gastric cancer histology (intestinal and non-intestinal) and controls in the stratified analysis (Table 3). </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion"><title><text><SENT sid="92" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="93" pm="."><plain>We evaluated a possible correlation between NOD2 Arg702Trp (rs2066844 C/T) polymorphism and gastric cancer susceptibility in a Romanian population, and no association was observed. </plain></SENT>
<SENT sid="94" pm="."><plain>Similar results were reported in several studies which assessed NOD2 mutations and gastric cancer susceptibility. </plain></SENT>
<SENT sid="95" pm="."><plain>The polymorphism Arg702Trp was not associated with histological types of gastric cancer, but 3020insC variant represents a risk factor for developing gastric cancer in Portugal, mainly for intestinal type [7]. </plain></SENT>
<SENT sid="96" pm="."><plain>Also, no association was found between NOD2 polymophisms and gastric cancer susceptibility in a German study that included 171 gastric cancer patients and 153 healthy controls [8]. </plain></SENT>
<SENT sid="97" pm="."><plain>In contrast, an Italian study which included 170 gastric cancer patients and 156 healthy controls reported that Arg702Trp and 1007fs polymorphisms were highly correlated with gastric cancer. </plain></SENT>
<SENT sid="98" pm="."><plain>Environmental carcinogens and NOD-induced proinflammatory cytokines could be possible reasons by which the studied polymorphisms may increase the risk for gastric cancer [9]. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>A meta-analysis evaluated several NOD2 polymorphisms such as rs2066842 C/T, rs2066844 C/T, rs2066845 C/G, rs2066847, L1007fsinsC and risk of cancer. </plain></SENT>
<SENT sid="100" pm="."><plain>The NOD2 rs2066844 C/T polymorphism was associated with increased risk of cancer for individuals bearing TT or CT genotype compared to individuals with CC genotype. </plain></SENT>
<SENT sid="101" pm="."><plain>The subgroup of analysis revealed that TT+CT genotype was associated with high risk of colorectal cancer, but there was no important association with the development of gastric cancer. </plain></SENT>
<SENT sid="102" pm="."><plain>This meta-analysis concluded that several NOD2 polymorphisms might be correlated with an increased risk of developing gastrointestinal cancers [10]. </plain></SENT>
</text></p><p><text><SENT sid="103" pm="."><plain>Different bacterial and viral impacts in the aetiology of cancer, as well as diagnostic and genotyping methods, differences in sample size, clinical and histological characteristics, ethnicity and chance have been suggested as possible explanations for controversial published findings in various populations [11]. </plain></SENT>
<SENT sid="104" pm="."><plain>NOD2 variants (Arg702Trp, Gly908Arg and 3020insC) could be risk factors in developing colorectal cancer, and a much higher frequency of all the mutations was found in the gastric cancer group compared to the healthy group in a Greek study [12]. </plain></SENT>
<SENT sid="105" pm="."><plain>Furthermore, NOD2 polymorphisms have been evaluated in relation with other pathological entities such as inflammatory bowel diseases (IBD) [13,14,15] and NOD2 variants are found associated with increased risk for developing IBD [16, 17]. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusion"><title><text><SENT sid="106" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="107" pm="."><plain>NOD2 Arg702Trp polymorphism is not correlated with gastric cancer risk in Romanian population and further investigations are needed to elucidate the contribution of NOD2 gene in gastric carcinogenesis. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="108" pm="."><plain>D.N.F, F.B., and M.G.C were supported by the project “Excellence program for multidisciplinary doctoral and postdoctoral research in chronic diseases”, Grant POSDRU/159/1.5/S/133377, supported by the Sectoral Operational Programme Human Resources Development 2007–2013, financed from the European Social Fund. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="109" pm="."><plain>1FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancerInt J Cancer2010127122893291721351269 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="110" pm="."><plain>2BorzutzkyAFriedAChouJBonillaFAKimSDedeogluFNOD2-associated diseases: Bridging innate immunity and autoinflammationClinImmunol20101343251261 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="111" pm="."><plain>3GayaDRRussellRKNimmoERSatsangiJNew genes in inflammatory bowel disease: lessons for complex diseases?Lancet200636795181271128416631883 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="112" pm="."><plain>4HenckaertsLVermeireSNOD2/CARD15 disease associations other than Crohn's diseaseInflamm Bowel Dis200713223524117206682 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="113" pm="."><plain>5Miceli-RichardCLesageSRybojadMPrieurAMManouvrier-HanuSHäfnerRChamaillardMZoualiHThomasGHugotJPCARD15 mutations in Blau syndromeNat Genet2001291192011528384 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="114" pm="."><plain>6KutikhinAGRole of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiologyHum Immunol20112710955968 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="115" pm="."><plain>7FreirePFigueiredoPCardosoRDonatoMMSáAPortelaFRomãozinhoJMSofiaCCard15 mutations and gastric cancer in a Portuguese populationScand J Gastroenterol201348101188119724047397 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="116" pm="."><plain>8WexTEbertMPKropfSDierkesJSchüttlerKRöckenCHöckerMMalfertheinerPGene polymorphisms of the NOD-2/CARD-15 gene and the risk of gastric cancer in GermanyAnticancer Res2008282A75776218507017 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="117" pm="."><plain>9AngelettiSGalluzzoSSantiniDRuzzoAVincenziBFerraroESpotoCLorinoGGrazianoNCalvieriAMagnaniMGrazianoFPantanoFToniniGDicuonzoGNOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian populationHum Immunol200970972973219397946 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="118" pm="."><plain>10JingweiLCaiyunHQianXChengzhongXYuanYNOD2 Polymorphisms Associated with Cancer Risk: A Meta-AnalysisPLoS One201492e89340e8934024586700 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="119" pm="."><plain>11KutikhinAGRole of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiologyHum Immunol2011721095596821745515 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="120" pm="."><plain>12PapaconstantinouITheodoropoulosGGazouliMPanoussopoulosDMantzarisGJFelekourasEBramisJAssociation between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek populationInt J Cancer2005114343343515578724 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="121" pm="."><plain>13HugotJPChamaillardMZoualiHLesageSCézardJPBelaicheJAlmerSTyskCO’MorainCAGassullMBinderVFinkelYCortotAModiglianiRLaurent-PuigPGowerRousseauCMacryJColombelJFSahbatouMThomasGAssociation of NOD2 leucine-rich repeat variants withsusceptibility to Crohn’s diseaseNature200141159960311385576 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="122" pm="."><plain>14OguraYBonenDKInoharaNNicolaeDLChenFFRamosRBrittonHMoranTKaraliuskasRDuerrRHAchkarJPBrantSRBaylessTMKirschnerBSHanauerSBNuñezGChoJHA frameshift mutation in NOD2associated with susceptibility to Crohn’s diseaseNature200141160360611385577 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="123" pm="."><plain>15HampeJCuthbertACroucherPJMirzaMMMascherettiSFisherSFrenzelHKingKHasselmeyerAMacPhersonAJBridgerSvan DeventerSForbesANikolausSLennard-JonesJEFoelschURKrawczakMLewisCSchreiberSMathewCGAssociation between insertionmutation in NOD2 gene and Crohn’s disease in German and British populationsLancet20013571925192811425413 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="124" pm="."><plain>16SventoraityteSZvirblieneAFrankeAKwiatkowskiRKiudelisGKupcinskasLSchreiberSNOD2, IL23R and ATG16L1 polymorphisms in Lithuanian patients with inflammatory bowel diseaseWorld J Gastroenterol201016335936420082483 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="125" pm="."><plain>17KanaanZMEichenbergerMRAhmadSWellerCRobertsHPanJRaiSNPetrasRWellerEBGalandiukSClinical predictors of inflammatory bowel disease in a genetically well-defined Caucasian populationJ Negat Results Biomed2012117722269043 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
